EGFR and central nervous system cancer: Several clinical and histopathological studies reported that amplification and overexpression of EGFR was associated with a shorter interval to relapse and poor survival in glioblastoma patients [33–35], low-grade glioma patients [36] and anaplastic astrocytoma patients [22, 32].